CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
